Gilead Scoops Most Rights to Ono’s Cancer Candidate
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences has acquired global rights outside selected Asian markets to an early clinical stage anticancer candidate being developed by Ono for B-cell malignancies and other potential indications.